FDA greenlights digital fix for lazy eye as safer device
Published Date: 4/22/2026
Rule
Summary
The FDA is officially classifying the digital therapy device for amblyopia (lazy eye) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool, innovative treatment faster and safer. The new classification is effective April 22, 2026, but it’s been in effect since October 20, 2021, so manufacturers can plan ahead without surprise costs or delays.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Class II makes amblyopia therapy more available
The FDA officially classified the digital therapy device for amblyopia as Class II (special controls), effective April 22, 2026, with the classification applicable on October 20, 2021. You (patients with amblyopia) may get faster and safer access to this digital treatment because the device faces lower regulatory hurdles than automatic Class III assignment.
De Novo decision creates a predicate device
Because FDA granted De Novo classification for this device (order issued October 20, 2021), the device can serve as a predicate for future substantially equivalent devices. Device sponsors can use the less-burdensome 510(k) route for future devices of this type instead of submitting additional De Novo requests or premarket approval applications.
Device remains subject to 510(k) premarket notification
The digital therapy device for amblyopia is subject to premarket notification under section 510(k) of the Federal Food, Drug, and Cosmetic Act unless and until FDA determines the device type should be exempt. At this time, FDA has not made an exemption determination, so sponsors must submit a 510(k).
Special controls require testing and labeling
To be Class II, digital therapy devices for amblyopia must meet special controls including: clinical performance testing (with evaluation of adverse events and measures of visual function); software verification, validation, and hazard analysis with documentation of technical specs; non-clinical performance and compatibility testing of all validated visual displays (resolution, luminance, contrast, field of view, image quality, optical image distance, interpupillary distance); labeling that lists minimum hardware/OS requirements, validated display models, length of treatment/retreatment supported by clinical testing, and a summary of clinical testing; and labeling comprehension testing with intended users.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-07860, Medical Devices; Immunology and Microbiology Devices; Classification of the Alzheimer's Disease Pathology Assessment Test
The FDA is officially putting the Alzheimer's Disease Pathology Assessment Test into Class II, meaning it now has special safety rules but fewer red tape hurdles. This change helps make the test safer and easier to get to patients, starting April 22, 2026, with the classification retroactive to May 4, 2022. Doctors, patients, and device makers will benefit from faster access to this important tool without extra costs or delays.
Next: 2026-07862, Medical Devices; Anesthesiology Devices; Classification of the Device for Sleep Apnea Testing Based on Mandibular Movement
The FDA is officially classifying devices that test sleep apnea by tracking jaw movement as Class II, meaning they have special safety rules but fewer hurdles than before. This change helps companies bring these devices to patients faster and safer, starting April 22, 2026, with the classification retroactive to January 7, 2022. Sleep apnea patients and device makers will benefit from easier access and clearer guidelines without extra costs.